Immunovant is a clinical-stage biopharmaceutical company developing antibody therapies that target the neonatal Fc receptor (FcRn) for autoimmune disease. Its pipeline centers on next-generation anti-FcRn candidates intended to lower pathogenic IgG antibodies across multiple indications. The company operates within the Roivant family of biotechs and does not yet market commercial products.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -120.6 | — |
| Q3 2025 | 0 | — | -126.5 | — |
| Q4 2025 | 0 | — | -110.6 | — |
| Q1 2026 | 0 | — | -147.9 | — |
| Q2 2026 | 0 | — | -153.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Hamilton Lane Incorporated (HLNE), Applied Digital Corporation (APLD), Weatherford International plc (WFRD), Frontdoor, Inc. (FTDR), Balchem Corporation (BCPC), RadNet, Inc. (RDNT)